Clene Inc.
For the period ended Dec 31, 2025. Filed Apr 10, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Dec 31, 2025 · Filed Apr 10, 2026
CLNN$3.95-0.5%Stored close · as of Nov 6, 2026
Contents
Summary Compensation Table
Summary Compensation Table -2025
The following table provides summary information concerning compensation awarded to, earned by, or paid to our NEOs for the years listed below:
| Name and Principal Position · Year · Salary · Bonus · Option Awards(1) · All Other Compensation · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Robert Etherington | 2025 | $508,763 | $— | $386,151 | $38,480 | (3) | $933,394 | |
| President and Chief Executive Officer | 2024 | $629,160 | $314,580 | (2) | $385,639 | $38,348 | $1,367,727 | |
| Mark Mortenson | 2025 | $412,017 | $— | $368,357 | $29,052 | (4) | $809,426 | |
| Chief Science Officer | 2024 | $496,480 | $198,592 | (2) | $354,562 | $28,985 | $1,078,619 | |
| Morgan R. Brown | 2025 | $292,578 | $— | $163,486 | $31,586 | (5) | $487,650 | |
| Chief Financial Officer | 2024 | $401,250 | $160,500 | (2) | $167,363 | $31,454 | $760,567 | |
| (1) | Stock option awards are valued using the Black-Scholes option pricing model. Due to the limited trading history of our Common Stock, the expected volatility is derived from the average historical stock volatilities of several unrelated comparable public companies within our industry, over a period equivalent to the expected term of the stock option grants. The risk-free interest rate for periods within the contractual life of the stock options is based on the U.S. Treasury yield curve in effect on the grant date. The expected dividend is assumed to be zero as we have never paid dividends and have no plans to do so. The expected term represents the period the stock options are expected to be outstanding. For option grants that are considered to be in the ordinary course, we determine the expected term using the simplified method, which considers the term to be the average of the time-to-vesting and the contractual life of the stock options. For other stock option grants, we estimate the expected term using historical data on employee exercises and post-vesting employment termination behavior, while also considering the contractual life of the award. The weighted average grant-date fair values of options granted for the years ended December 31, 2025 and 2024 were $3.95 and $5.95, respectively. |
| (2) | Bonus earned but not paid due to the Company’s cost-saving initiatives. Payment is subject to the Company’s ability to raise additional funding. |
| (3) | The amount reported reflects $4,500 of 401(k) contributions matched by us and $33,980 of health benefits and life and disability insurance that we paid for on behalf of Mr. Etherington during the last fiscal year. |
| (4) | The amount reported reflects $4,500 of 401(k) contributions matched by us and $24,552 of health benefits and life and disability insurance that we paid for on behalf of Mr. Mortenson during the last fiscal year. |
| (5) | The amount reported reflects $4,500 of 401(k) contributions matched by us and $27,086 of health benefits and life and disability insurance that we paid for on behalf of Mr. Brown during the last fiscal year. |
We do not grant equity awards in anticipation of the release of material nonpublic information, and we do not time the release of material nonpublic information based on equity award grant dates.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.